Aptus Pharma Ltd (APPL) — shareholding pattern, promoter holding, financials and share price
About Aptus Pharma Ltd (APPL)
Aptus Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as APPL and on the BSE under scrip code 544529. Its ISIN is INE15XJ01010.
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. [1]
Listed peers in Pharmaceuticals: Transchem Ltd, Albert David Ltd, Astal Laboratories Ltd, Valiant Laboratories Ltd, Medicamen Biotech Ltd, Medico Remedies Ltd.
Valuation & Returns
10 Jul 2026At ₹224 a share on 10 Jul 2026, Aptus Pharma Ltd (APPL) was valued at a price-to-earnings ratio of 83.15x against an industry P/E of 36.41x and a price-to-book of 19.22x on a book value of ₹11.65 per share. Solomo computes return on equity of 19.79% and return on capital employed of 23.5% from filed results.
- P/E
- 83.15x
- Industry P/E
- 36.41x
- P/B
- 19.22x
- EPS (TTM)
- ₹6.37
- Book value / share
- ₹11.65
- ROE
- 19.79%
- ROCE
- 23.5%
- ROA
- 10.61%
- Debt / equity
- 0.31x
- Dividend yield
- 0%
- EBITDA margin
- 16.25%
- 52-week range
- ₹32.32 – ₹238.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aptus Pharma Ltd (APPL) reported revenue of ₹46.57 crore, net profit of ₹4.62 crore and earnings per share of ₹2.69. That compares with revenue of ₹24.56 crore and net profit of ₹3.1 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹32.2 crore and net profit ₹2.87 crore (standalone).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 13.9 | 17.81 | 24.56 | 46.57 |
| Net profit (₹ cr) | 0.19 | 0.8 | 3.1 | 4.62 |
| EPS (₹) | 2.38 | 10 | 2.48 | 2.69 |
| Measure | 1Y |
|---|---|
| Sales growth | 37.51% |
| Profit growth | 287.50% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.89% of Aptus Pharma Ltd (APPL) (unchanged from the previous quarter). Market capitalisation was ₹384 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Jun 2026: HUF 2.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.89% | - | - | - | 27.11% |
| Mar 2026 | 72.89% | - | - | - | 27.11% |
| Dec 2025 | 72.89% | - | - | - | 27.11% |
| Sep 2025 | 72.89% | - | 10.03% | 2.8% | 27.11% |